Pharma stocks do not normally lead turnover on the Dhaka Stock Exchange. Engineering does. Banking does. On a good day, telecom might. But on March 29, pharmaceuticals captured 17.6% of all trading volume — the highest sectoral share of the session — while the broad market was falling. That number demands an explanation, and the two possible answers lead to very different conclusions about what happens next.
The DSEX closed at 5,272, shedding 44.2 points or 0.83% from the previous session’s close of 5,316. Most scrips ended in the red. Selling pressure persisted throughout the day with partial recovery attempts meeting fresh supply. Yet total turnover climbed 7.1% to Taka 6.4 billion, up from Taka 6.0 billion in the prior session. A falling index with rising turnover tells you that money is not leaving the market. It is moving.
The question is where it moved, and why.
The Sectoral Shift in Four Days
Compare March 25 to March 29 and the rotation becomes visible.
On March 25, engineering led all sectors with a 13.6% turnover share. Pharma sat second at 12.7%. Banking held third at 11.1%. That distribution was normal — cyclical sectors leading during a recovery session, with pharma playing its usual supporting role.
Four trading days later, the order had changed entirely. Pharma surged to 17.6% — a nearly five-percentage-point jump. Engineering slipped to 12.9%. Banking faded to 9.9%. In a market where the index was declining and most stocks were losing ground, almost one in five taka of trading activity flowed through pharmaceutical counters.
A five-point swing in sectoral turnover share over four sessions is not noise. Something structural shifted. But what?
The Case for Defensive Rotation
The first explanation is straightforward and has precedent. When uncertainty rises, institutional money rotates out of cyclical sectors and into non-cyclical ones. Pharmaceuticals are the textbook defensive play — people buy medicine regardless of what the DSEX does or what is happening in the Middle East.
The timing supports this reading. Middle East conflict uncertainties have been the dominant macro overhang for weeks. On March 29, that pressure sustained selling across the board. In that environment, pharma’s essential-demand characteristics become attractive to portfolio managers who need equity exposure but want to reduce cyclical risk.
The valuation argument strengthens the case. The pharma sector is trading at a price-to-earnings ratio of 10.2x against a three-year average of 14.5x. That is a 30% discount to its own historical mean. For an institutional buyer looking for a sector that combines defensive cash flows with valuation support, pharma at 10.2x P/E is the most logical destination on the DSE right now.
If this reading is correct, the turnover surge is accumulation. Smart money buying pharma at a discount while the rest of the market panics.
The Case for Profit-Taking
The second explanation is less comfortable. Pharma may be one of the few sectors where investors still have gains to harvest. After weeks of broad decline, portfolio managers sitting on green pharma positions could be liquidating to raise cash — either to meet margin requirements elsewhere, fund redemptions, or simply reduce total exposure.
Under this reading, the turnover surge is distribution, not accumulation. High volume is not buyers competing for shares. It is sellers finding enough liquidity in pharma counters to execute exits that are impossible in illiquid sectors where stocks sit on floor prices with no bids.
The distinction matters enormously. Defensive rotation means pharma holds up or rises from here. Profit-taking means the sector absorbs selling pressure until the sellers are done — and then it falls too.
What the Surrounding Data Suggests
Three signals tilt the balance toward rotation rather than liquidation.
First, turnover rose while the index fell. If pharma holders were panic-selling, you would expect to see total turnover decline as buyers withdraw. Instead, Taka 6.4 billion changed hands — 7.1% more than the prior session. That increase has to come from somewhere, and incremental buying in pharma is the most consistent explanation.
Second, the DS30 blue-chip index tracked the DSEX decline rather than amplifying it. Concentrated liquidation in large-cap pharma names like Square Pharmaceuticals, Beximco Pharma, and Renata Limited would have dragged the DS30 disproportionately. Broad-based decline without blue-chip amplification suggests orderly repositioning, not forced selling.
Third, banking and engineering gave up turnover share. Money did not just flow into pharma — it visibly drained from cyclical sectors. Banking dropped from 11.1% to 9.9%. Engineering fell from 13.6% to 12.9%. That pattern — cyclical sectors losing share while a defensive sector gains — is the textbook signature of institutional rotation.
What to Watch Next
None of this is conclusive. The definitive answer will come from individual stock-level data over the next two to three sessions. If Square Pharma, Beximco Pharma, and Renata close flat or higher while the DSEX continues declining, the rotation thesis holds. If those names start breaking lower on sustained volume, the profit-taking thesis wins.
Watch the 10.2x sector P/E as your benchmark. A price-to-book compression below book value in major pharma names would signal that even the defensive trade is failing — and that is when the entire market’s floor becomes uncertain.
For now, the data leans toward defensive rotation. But the margin is thin, and in a market driven by geopolitical headlines rather than fundamentals, a single news cycle can flip the script overnight.
This analysis is for informational purposes only and does not constitute investment advice. Consult a BSEC-licensed adviser before making investment decisions.